Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Respiratory Medicine Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Exploring Pneumonia: Understanding its Epidemiology, Deciphering Pathogenic Complexities, and Developing Advanced Diagnostic and Therapeutic Approaches

Abstract

Pneumonia, a widespread respiratory infection affecting the alveoli and lung parenchyma, continues to be a major global health concern, particularly in children. Despite advancements in vaccine development and anti-infective therapies, pneumonia is a leading cause of death, particularly among children and the elderly. It accounts for approximately 14% of all deaths in children under five years of age globally, with over 700,000 deaths occurring annually. In adults, especially those over 65 years of age, pneumonia significantly increases mortality, contributing to over 1 million deaths yearly worldwide. Community-acquired Pneumonia (CAP) is predominantly caused by , , and . is the leading pathogen, particularly in infants, the elderly, and immunocompromised individuals, often resulting in severe clinical presentations. causes milder, atypical pneumonia, commonly referred to as “walking pneumonia”, affecting young adults and adolescents. is also a significant cause of mild to moderate respiratory infections, particularly in school-aged children. The identification of these pathogens is critical for guiding empirical antimicrobial therapy, as the clinical severity and response to treatment vary with each microorganism. This review aimed to explore the intricacies of pneumonia pathogenesis and provide insights into the role of various microorganisms in its development. By emphasizing the importance of timely and appropriate antimicrobial therapy, the review further aims to underscore the need for rapid, accurate diagnostic tests capable of detecting pathogens and antibiotic resistance. Therefore, improving diagnostic capabilities and targeted treatments is essential for effective pneumonia management. The complexity of pneumonia pathogenesis and the variety of causative microorganisms require rapid, accurate diagnostic tests to guide appropriate therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X339936250107062518
2025-01-20
2025-04-06

  • From This Site

    /content/journals/crmr/10.2174/011573398X339936250107062518
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Hippocrates The genuine works of Hippocrates, 1:324. Translated from the Greek with a preliminary discourse and annotations by Francis Adams. London Sydenham Society 1849
    [Google Scholar]
  2. Laennec R.T. A treatise on the diseases of the chest and on mediate auscultation. Translated from the 3rd French ed. by J. Forbes, with notes of Prof. Andral from the 4th ed SS & Wm. Wood New York 1838
    [Google Scholar]
  3. Rokitansky C. Inflammations of the lungs (pneumonia). Manual of Pathological Anatomy. London Sydenham Society 1852
    [Google Scholar]
  4. Lim W.S. Pneumonia—Overview. Encyclopedia of Respiratory Medicine Academic Press 2022 185 197 10.1016/B978‑0‑12‑801238‑3.11636‑8
    [Google Scholar]
  5. Mandell L.A. Niederman M.S. Aspiration pneumonia. N. Engl. J. Med. 2019 380 7 651 663 10.1056/NEJMra1714562 30763196
    [Google Scholar]
  6. Wu B.G. Segal L.N. The lung microbiome and its role in pneumonia. Clin. Chest Med. 2018 39 4 677 689 10.1016/j.ccm.2018.07.003 30390741
    [Google Scholar]
  7. José R.J. Periselneris J.N. Brown J.S. Community-acquired pneumonia. Curr. Opin. Pulm. Med. 2015 21 3 212 218 10.1097/MCP.0000000000000150 25775050
    [Google Scholar]
  8. Kieninger A.N. Lipsett P.A. Hospital-acquired pneumonia: Pathophysiology, diagnosis, and treatment. Surg. Clin. North Am. 2009 89 2 439 461, ix 10.1016/j.suc.2008.11.001 19281893
    [Google Scholar]
  9. Modi A.R. Kovacs C.S. Hospital-acquired and ventilator-associated pneumonia: Diagnosis, management, and prevention. Cleve. Clin. J. Med. 2020 87 10 633 639 10.3949/ccjm.87a.19117 33004324
    [Google Scholar]
  10. Kohbodi G. A. Rajasurya V. Ventilator-associated pneumonia. StatPearls StatPearls Publishing 2023
    [Google Scholar]
  11. Sattar S. B. A. Bacterial pneumonia. StatPearls StatPearls Publishing 2023
    [Google Scholar]
  12. Cillóniz C. Ewig S. Polverino E. Marcos M.A. Esquinas C. Gabarrús A. Mensa J. Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011 66 4 340 346 10.1136/thx.2010.143982 21257985
    [Google Scholar]
  13. Torres A. Niederman M.S. Chastre J. Ewig S. Fernandez-Vandellos P. Hanberger H. Kollef M. Li Bassi G. Luna C.M. Martin-Loeches I. Paiva J.A. Read R.C. Rigau D. Timsit J.F. Welte T. Wunderink R. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur. Respir. J. 2017 50 3 1700582 10.1183/13993003.00582‑2017 28890434
    [Google Scholar]
  14. Prina E. Ranzani O.T. Torres A. Community-acquired pneumonia. Lancet 2015 386 9998 1097 1108 10.1016/S0140‑6736(15)60733‑4 26277247
    [Google Scholar]
  15. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020 396 10258 1204 1222 10.1016/S0140‑6736(20)30925‑9
    [Google Scholar]
  16. Komiya K. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Infect. Dis. 2018 18 11 1191 1210 10.1016/S1473‑3099(18)30310‑4
    [Google Scholar]
  17. Komiya K. Rubin B.K. Kadota J. Mukae H. Akaba T. Moro H. Aoki N. Tsukada H. Noguchi S. Shime N. Takahashi O. Kohno S. Prognostic implications of aspiration pneumonia in patients with community acquired pneumonia: A systematic review with meta-analysis. Sci. Rep. 2016 6 1 38097 10.1038/srep38097 27924871
    [Google Scholar]
  18. Torres A. Peetermans W.E. Viegi G. Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax 2013 68 11 1057 1065 10.1136/thoraxjnl‑2013‑204282 24130229
    [Google Scholar]
  19. Farooqui H. Jit M. Heymann D.L. Zodpey S. Burden of severe pneumonia, pneumococcal pneumonia and pneumonia deaths in indian states: Modelling based estimates. PLoS One 2015 10 6 e0129191 10.1371/journal.pone.0129191 26086700
    [Google Scholar]
  20. Eshwara V. Mukhopadhyay C. Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian J. Med. Res. 2020 151 4 287 302 10.4103/ijmr.IJMR_1678_19 32461392
    [Google Scholar]
  21. Grousd J.A. Rich H.E. Alcorn J.F. Host-pathogen interactions in gram-positive bacterial pneumonia. Clin. Microbiol. Rev. 2019 32 3 e00107-18 10.1128/CMR.00107‑18 31142498
    [Google Scholar]
  22. Parker D. Ahn D. Cohen T. Prince A. Innate immune signaling activated by MDR bacteria in the airway. Physiol. Rev. 2016 96 1 19 53 10.1152/physrev.00009.2015 26582515
    [Google Scholar]
  23. Kutter J.S. Spronken M.I. Fraaij P.L. Fouchier R.A.M. Herfst S. Transmission routes of respiratory viruses among humans. Curr. Opin. Virol. 2018 28 142 151 10.1016/j.coviro.2018.01.001 29452994
    [Google Scholar]
  24. Phillips-Houlbracq M. Ricard J.D. Foucrier A. Yoder-Himes D. Gaudry S. Bex J. Messika J. Margetis D. Chatel J. Dobrindt U. Denamur E. Roux D. Pathophysiology of escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. Int. J. Med. Microbiol. 2018 308 2 290 296 10.1016/j.ijmm.2018.01.003 29325882
    [Google Scholar]
  25. Walter J.M. Wunderink R.G. Severe respiratory viral infections. Infect. Dis. Clin. North Am. 2017 31 3 455 474 10.1016/j.idc.2017.05.004 28687214
    [Google Scholar]
  26. Mizgerd J.P. Inflammation and Pneumonia. Clin. Chest Med. 2018 39 4 669 676 10.1016/j.ccm.2018.07.002 30390740
    [Google Scholar]
  27. Guin D. Yadav S. Singh P. Singh P. Thakran S. Kukal S. Kanojia N. Paul P.R. Pattnaik B. Sardana V. Grover S. Hasija Y. Saso L. Agrawal A. Kukreti R. Human genetic factors associated with pneumonia risk, a cue for COVID-19 susceptibility Infection, genetics and evolution. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2022 102 105299
    [Google Scholar]
  28. Santoro F. Iannelli F. Pozzi G. Genomics and genetics of streptococcus pneumoniae. Microbiol. Spectr. 2019 7 3
    [Google Scholar]
  29. Lamping D.L. Schroter S. Marquis P. Marrel A. Duprat-Lomon I. Sagnier P.P. The community-acquired pneumonia symptom questionnaire: A new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia. Chest 2002 122 3 920 929 10.1378/chest.122.3.920 12226033
    [Google Scholar]
  30. Mattila J.T. Fine M.J. Limper A.H. Murray P.R. Chen B.B. Lin P.L. Pneumonia. Treatment and diagnosis. Ann. Am. Thorac. Soc. 2014 11 4 S189 S192
    [Google Scholar]
  31. Bhuiyan M.U. Blyth C.C. West R. Lang J. Rahman T. Granland C. de Gier C. Borland M.L. Thornton R.B. Kirkham L.A.S. Martin A. Richmond P.C. Smith D.W. Jaffe A. Snelling T.L. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. BMC Pulm. Med. 2019 19 1 71 10.1186/s12890‑019‑0835‑5 30940126
    [Google Scholar]
  32. Kobayashi S.D. DeLeo F.R. Role of neutrophils in innate immunity: A systems biology-level approach. Wiley Interdiscip. Rev. Syst. Biol. Med. 2009 1 3 309 333 10.1002/wsbm.32 20836000
    [Google Scholar]
  33. Guo K. Cheng J. Li K. Wang L. Lv Y. Cao D. Diagnosis and detection of pneumonia using weak-label based on X-ray images: A multi-center study. BMC Med. Imaging 2023 23 1 209 10.1186/s12880‑023‑01174‑4 38087255
    [Google Scholar]
  34. Torres A. Cillóniz C. Clinical Management of Bacterial Pneumonia. 2015 10.1007/978‑3‑319‑22062‑8
    [Google Scholar]
  35. Torres A. Cilloniz C. Niederman M.S. Menéndez R. Chalmers J.D. Wunderink R.G. van der Poll T. Pneumonia. Nat. Rev. Dis. Primers 2021 7 1 25 10.1038/s41572‑021‑00259‑0 33833230
    [Google Scholar]
  36. Kalil A.C. Metersky M.L. Klompas M. Muscedere J. Sweeney D.A. Palmer L.B. Napolitano L.M. O’Grady N.P. Bartlett J.G. Carratalà J. El Solh A.A. Ewig S. Fey P.D. File T.M. Jr Restrepo M.I. Roberts J.A. Waterer G.W. Cruse P. Knight S.L. Brozek J.L. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the american thoracic society. Clin. Infect. Dis. 2016 63 5 e61 e111 10.1093/cid/ciw353 27418577
    [Google Scholar]
  37. Metlay J.P. Waterer G.W. Long A.C. Anzueto A. Brozek J. Crothers K. Cooley L.A. Dean N.C. Fine M.J. Flanders S.A. Griffin M.R. Metersky M.L. Musher D.M. Restrepo M.I. Whitney C.G. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am. J. Respir. Crit. Care Med. 2019 200 7 e45 e67 10.1164/rccm.201908‑1581ST 31573350
    [Google Scholar]
  38. Claessens Y.E. Debray M.P. Tubach F. Brun A.L. Rammaert B. Hausfater P. Naccache J.M. Ray P. Choquet C. Carette M.F. Mayaud C. Leport C. Duval X. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2015 192 8 974 982 10.1164/rccm.201501‑0017OC 26168322
    [Google Scholar]
  39. Ding X. Xu J. Zhou J. Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur. J. Radiol. 2020 127 109009 10.1016/j.ejrad.2020.109009 32325282
    [Google Scholar]
  40. Long L. Zhao H.T. Zhang Z.Y. Wang G.Y. Zhao H.L. Lung ultrasound for the diagnosis of pneumonia in adults. Medicine 2017 96 3 e5713 10.1097/MD.0000000000005713 28099332
    [Google Scholar]
  41. Musher D.M. Montoya R. Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 2004 39 2 165 169 10.1086/421497 15307023
    [Google Scholar]
  42. Fukuyama H. Yamashiro S. Kinjo K. Tamaki H. Kishaba T. Validation of sputum Gram stain for treatment of community-acquired pneumonia and healthcare-associated pneumonia: A prospective observational study. BMC Infect. Dis. 2014 14 1 534 10.1186/1471‑2334‑14‑534 25326650
    [Google Scholar]
  43. Smith M.D. Derrington P. Evans R. Creek M. Morris R. Dance D.A.B. Cartwright K. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: A prospective, controlled clinical evaluation. J. Clin. Microbiol. 2003 41 7 2810 2813 10.1128/JCM.41.7.2810‑2813.2003 12843005
    [Google Scholar]
  44. Mustafa Hellou M. Górska A. Mazzaferri F. Cremonini E. Gentilotti E. De Nardo P. Poran I. Leeflang M.M. Tacconelli E. Paul M. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2021 27 3 341 351
    [Google Scholar]
  45. Yu V.L. Stout J.E. Rapid diagnostic testing for community-acquired pneumonia: Can innovative technology for clinical microbiology be exploited? Chest 2009 136 6 1618 1621 10.1378/chest.09‑0939 19995763
    [Google Scholar]
  46. Balows A. Manual of clinical microbiology 8th ed ASM Press 2003 2 2113 10.1016/S0732‑8893(03)00160‑3
    [Google Scholar]
  47. Saukkoriipi A. Palmu A. Kilpi T. Leinonen M. Real-time quantitative PCR for the detection of Streptococcus pneumoniae in the middle ear fluid of children with acute otitis media. Mol. Cell. Probes 2002 16 5 385 390 10.1006/mcpr.2002.0443 12477443
    [Google Scholar]
  48. She R.C. Thurber A. Hymas W.C. Stevenson J. Langer J. Litwin C.M. Petti C.A. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections. J. Clin. Microbiol. 2010 48 9 3380 3382 10.1128/JCM.00321‑10 20610673
    [Google Scholar]
  49. Dung T.T.N. Phat V.V. Vinh C. Lan N.P.H. Phuong N.L.N. Ngan L.T.Q. Thwaites G. Thwaites L. Rabaa M. Nguyen A.T.K. Duy P.T. Development and validation of multiplex real-time PCR for simultaneous detection of six bacterial pathogens causing lower respiratory tract infections and antimicrobial resistance genes. BMC Infect. Dis. 2024 24 1 164 10.1186/s12879‑024‑09028‑2 38326753
    [Google Scholar]
  50. Fox J.D. Nucleic acid amplification tests for detection of respiratory viruses. J. Clin. Virol. 2007 40 Suppl. 1 S15 S23
    [Google Scholar]
  51. Shariatzadeh M. R. Marrie T. J. Does sputum culture affect the management and/or outcome of community-acquired pneumonia? E. Mediterr. Health J. 2009 15 4 792 799
    [Google Scholar]
  52. Bartlett J.G. Decline in microbial studies for patients with pulmonary infections. Clin. Infect. Dis. 2004 39 2 170 172 10.1086/421498 15307024
    [Google Scholar]
  53. Fang Z. Liu Q. Tang W. Yu H. Zou M. Zhang H. Xue H. Lin S. Pei Y. Ai J. Chen J. Experience in the diagnosis and treatment of pneumonia caused by infection with Tropheryma whipplei: A case series. Heliyon 2023 9 6 e17132 10.1016/j.heliyon.2023.e17132 37484369
    [Google Scholar]
  54. Torres A. Artigas A. Ferrer R. Biomarkers in the ICU: Less is more? No. Intensive Care Med. 2021 47 1 97 100 10.1007/s00134‑020‑06271‑4 33057749
    [Google Scholar]
  55. Liu P. Ohl C. Johnson J. Williamson J. Beardsley J. Luther V. Frequency of empiric antibiotic de-escalation in an acute care hospital with an established antimicrobial stewardship program. BMC Infect. Dis. 2016 16 1 751 10.1186/s12879‑016‑2080‑3 27955625
    [Google Scholar]
  56. Wunderink R.G. Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ 2017 358 j2471 10.1136/bmj.j2471 28694251
    [Google Scholar]
  57. Krishnamurthy A. Palombo E. Current therapeutics and prophylactic approaches to treat pneumonia. The Microbiology of Respiratory System Infections Academic Press 2016 1 263 279 10.1016/B978‑0‑12‑804543‑5.00017‑8
    [Google Scholar]
  58. File T.M. Jr Low D.E. Eckburg P.B. Talbot G.H. Friedland H.D. Lee J. Llorens L. Critchley I.A. Thye D.A. Pullman J. Giordano P. Welker J. Manos P. Mehra P. File T. De Santo J. Venkateswaralu B. Gerald Schrock C. Tillis W. Winetz J.A. Gonzalez J.M. Ramage A. Eisenhower D.D. Koegelenberg C. Engelbrecht I. Jurgens J. Mitha I. Breedt J. Gani M. Roos J. Basson M. Van Zyl L. Meeding R. Fulat M. Le Roux M. Bonvehi P.E. Ganaha M.C. Gurini A.L. Daniel Lopardo G. Cristina L. Edwardo Prieto S. Rodiguez C.G. Augusto Teijeiro R. Carmen Pallone E. Pryluka D.H. da Cunha C.A. da Silva N.B. de Faria Freire A.T. Ferreira Starling C.E. Costa Fiterman J. Gongora Rubio F. Carlos Losso L. Patelli M. Souza Lima J. Zimermann Teixeira P.J. Carmo Moreira M.A. Abreu de Oliveira J.C. Roudas V. Gamal E.A. Leschenko I. Rudnov V.A. Yevdokimova A.G. Vertkin A.L. Ambalov Y.M. Dvoryashina I.V. Zilber E. Khamitov R.F. Galustyan A.N. Reshetko O.V. Senior V.A. Grosan M.F. Jimborean G. Lupse M. Aron G. Olteanu D. Puschita M. Gavris C. Tudorache V.M. Youroukova V. Petkova M. Troshanova E. Dzhabalyan M. Kavtaradze G. Makhviladze M. Tabukashvili R. Pons M. Garbino J. Genne D. Rothen M. de Saracho J.O. Capelastegui A. Menendez R. Torres A. Shum C. Falco V. Bouza E. Bru J-P. Misset B. Megarbane B. Sollet J.P. Molina J-M. Dalhoff K. Lorenz J. Petermann W. Rohde G. Schumann C. Tasci S. Zerbst J. Auch-Schwelk W. Suttorp N. Henrich R. Fertl A. Grohe C. Jakobeit C. Deppermann K-M. Batura-Gabryel H. Pupek-Musialik D. Piotrowicz P. Marcisz C. Czarnobilski K. Jankowska R. Janik K. Gutowska-Jablonska M. Hamankiewicz M. Kus J. Rydzewski A. Dulawa J. Ziolko E. Baranska E. Wendland M. Trebas-Pietras E. Tyszkiewic I. Bonelli J. Baliko Z. Bisits M. Losonczy G. Mark Z. Albert I. Francovszky E. Fonay K. Tetiana Pertseva T. Yefimov V. Havrysyuk V. Melnyk V. Yashyna L. Monogarova N. Kolchyn Y. Dutka R. Smolyanyi O. Tryshchuk N. Kaydashev I. Rodionova V. Neyko V. Chopey I. Alekniene B. Kramilius G. Naudziunas S. Miliauskas S. Nausediene V. Valavicius A. Mitic-Milikic M. Celeketic D. Lazic Z. Milinic N. Pejcic T. Sukles K. Jaanus M. Meriste S. Ahmad Mahayiddin D.H.A. Bin Abdul Muttalif A.P. Kuang Kiat K. Binte R. Manap A. bt Md Tarekh N.A. Anekthananon T. Mootsikapun P. Intalapaporn P. Pothirat C. Horsin P. Churchottaworn C. Wattanathum A. Dukat A. Plutinsky J. FOCUS 1 investigators FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 2011 66 Suppl. 3 iii19 iii32 10.1093/jac/dkr096 21482566
    [Google Scholar]
  59. Kazmierczak K.M. Biedenbach D.J. Hackel M. Rabine S. de Jonge B.L.M. Bouchillon S.K. Sahm D.F. Bradford P.A. Global dissemination of bla KPC into bacterial species beyond klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob. Agents Chemother. 2016 60 8 4490 4500 10.1128/AAC.00107‑16 27161636
    [Google Scholar]
  60. Bassetti M. Echols R. Matsunaga Y. Ariyasu M. Doi Y. Ferrer R. Lodise T.P. Naas T. Niki Y. Paterson D.L. Portsmouth S. Torre-Cisneros J. Toyoizumi K. Wunderink R.G. Nagata T.D. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 2021 21 2 226 240 10.1016/S1473‑3099(20)30796‑9 33058795
    [Google Scholar]
  61. Jones R.N. Sader H.S. Mendes R.E. Flamm R.K. Update on antimicrobial susceptibility trends among streptococcus pneumoniae in the united states: Report of ceftaroline activity from the sentry antimicrobial surveillance program (1998–2011). Diagn. Microbiol. Infect. Dis. 2013 75 1 107 109 10.1016/j.diagmicrobio.2012.08.024 23009730
    [Google Scholar]
  62. Wu J.Y. Srinivas P. Pogue J.M. Cefiderocol: A novel agent for the management of multidrug-resistant gram-negative organisms. Infect. Dis. Ther. 2020 9 1 17 40 10.1007/s40121‑020‑00286‑6 32072491
    [Google Scholar]
  63. File T.M. Jr Goldberg L. Das A. Sweeney C. Saviski J. Gelone S.P. Seltzer E. Paukner S. Wicha W.W. Talbot G.H. Gasink L.B. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: The phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin. Infect. Dis. 2019 69 11 1856 1867 10.1093/cid/ciz090 30722059
    [Google Scholar]
  64. Alexander E. Goldberg L. Das A.F. Moran G.J. Sandrock C. Gasink L.B. Spera P. Sweeney C. Paukner S. Wicha W.W. Gelone S.P. Schranz J. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia. JAMA 2019 322 17 1661 1671 10.1001/jama.2019.15468 31560372
    [Google Scholar]
  65. He Y.S. Yang M. Liu G. Ji J. Qian S.Y. Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia. Pediatr. Pulmonol. 2023 58 7 2017 2024 10.1002/ppul.26426 37098833
    [Google Scholar]
  66. Monteiro J.F. Hahn S.R. Gonçalves J. Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol. Res. Perspect. 2018 6 4 e00420 10.1002/prp2.420 30156005
    [Google Scholar]
  67. Hsu H.C. Huang P.W. Cho Y.T. Chu C.Y. Cotrimoxazole as a preventative intervention for pneumocystis pneumonia in pemphigus patients treated with rituximab: A retrospective study. Dermatol. Ther. 2023 13 7 1561 1576 10.1007/s13555‑023‑00953‑9 37322166
    [Google Scholar]
  68. Iregui M. Ward S. Sherman G. Fraser V.J. Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002 122 1 262 268 10.1378/chest.122.1.262 12114368
    [Google Scholar]
  69. Shindo Y. Ito R. Kobayashi D. Ando M. Ichikawa M. Goto Y. Fukui Y. Iwaki M. Okumura J. Yamaguchi I. Yagi T. Tanikawa Y. Sugino Y. Shindoh J. Ogasawara T. Nomura F. Saka H. Yamamoto M. Taniguchi H. Suzuki R. Saito H. Kawamura T. Hasegawa Y. Central Japan Lung Study Group Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: An observational cohort study. Lancet Infect. Dis. 2015 15 9 1055 1065 10.1016/S1473‑3099(15)00151‑6 26145194
    [Google Scholar]
  70. Brambilla A.M. Aliberti S. Prina E. Nicoli F. Forno M.D. Nava S. Ferrari G. Corradi F. Pelosi P. Bignamini A. Tarsia P. Cosentini R. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med. 2014 40 7 942 949 10.1007/s00134‑014‑3325‑5 24817030
    [Google Scholar]
  71. Mantero M. Tarsia P. Gramegna A. Henchi S. Vanoni N. Di Pasquale M. Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of recommendations. Multidiscip. Respir. Med. 2017 12 1 26 10.1186/s40248‑017‑0106‑3 29034094
    [Google Scholar]
  72. Saiman L. Marshall B.C. Mayer-Hamblett N. Burns J.L. Quittner A.L. Cibene D.A. Coquillette S. Fieberg A.Y. Accurso F.J. Campbell P.W. III for the Macrolide Study Group Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003 290 13 1749 1756 10.1001/jama.290.13.1749 14519709
    [Google Scholar]
  73. Agarwal A.K. Raja A. Brown B.D. Chronic obstructive pulmonary disease. StatPearls. StatPearls Publishing 2023
    [Google Scholar]
  74. Walters J.A.E. Tang J.N.Q. Poole P. Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Libr. 2017 2019 3 CD001390 10.1002/14651858.CD001390.pub4 28116747
    [Google Scholar]
  75. Luna C.M. Impact of vaccination on the epidemiology and prognosis of pneumonia. Rev. Esp. Quimioter. 2022 35 1 104 110
    [Google Scholar]
  76. Nabi B. Rehman S. Aggarwal S. Baboota S. Ali J. Nano-based anti-tubercular drug delivery: An emerging paradigm for improved therapeutic intervention. Drug Deliv. Transl. Res. 2020 10 4 1111 1121 10.1007/s13346‑020‑00786‑5 32418158
    [Google Scholar]
  77. Worthington R.J. Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013 31 3 177 184 10.1016/j.tibtech.2012.12.006 23333434
    [Google Scholar]
  78. Marsh D. Bartucci R. Sportelli L. Lipid membranes with grafted polymers: Physicochemical aspects. Biochim. Biophys. Acta Biomembr. 2003 1615 1-2 33 59 10.1016/S0005‑2736(03)00197‑4 12948586
    [Google Scholar]
  79. Smola M. Vandamme T. Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomedicine 2008 3 1 1 19 18488412
    [Google Scholar]
/content/journals/crmr/10.2174/011573398X339936250107062518
Loading
Exploring Pneumonia: Understanding its Epidemiology, Deciphering Pathogenic Complexities, and Developing Advanced Diagnostic and Therapeutic Approaches
Bentham Science Publishers ; https://doi.org/10.2174/011573398X339936250107062518
/content/journals/crmr/10.2174/011573398X339936250107062518
/content/journals/crmr/10.2174/011573398X339936250107062518
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Community-acquired pneumonia ; diagnostic tests ; pathogenesis ; hospital-acquired pneumonia ; pathogens ; ventilation-associated pneumonia ; microbial etiology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test